Australia's Pharmaceutical Benefits Scheme Puts Damper On Roche's Avastin Sales
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sales of the top 20 cancer drugs in Australia totaled $545 million in 2008, representing a growth rate of 30 percent since 2005, according to a recent Datamonitor report
You may also be interested in...
New Zealand Ministry Of Health Overturns PHARMAC Decision To Decline Funding Roche 12-Month Herceptin Treatment: New Zealand Regulatory Roundup
PERTH, Australia - After much heated debate, New Zealand's newly elected National Party has overturned the Pharmaceutical Management Agency's decision to decline funding for 12-month treatment of Roche's Herceptin (trastuzumab) for HER2-positive early breast cancer treatment
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).